BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
2
조회
0
다운로드
0
인용
0
참고문헌
초록
BIX01294 (BIX), an inhibitor of the G9a histone methyltransferase, has been reported to have antitumor activity against a variety of cancers. However, the molecular mechanisms underlying its anticancer effects, particularly those against lung cancer, remain unclear. Here, we report that BIX induces apoptotic cell death in EGFR-mutant non-small cell lung cancer (NSCLC) cells but not in their wild-type counterparts. Treatment with BIX resulted in a significant reduction in the EGFR level and inhibition of EGFR signaling only in EGFR-mutant NSCLC cells, leading to apoptosis. BIX also inhibited mitochondrial metabolic function and decreased the cellular energy levels that are critical for maintaining the EGFR level. Furthermore, BIX transcriptionally downregulated the transcription of branched-chain α-keto acid dehydrogenase (BCKDHA), which is essential for fueling the tricarboxylic acid (TCA) cycle. Interestingly, this BCKDHA downregulation was due to inhibition of Jumanji-domain histone demethylases but not the G9a histone methyltransferase. We observed that KDM3A, a Jumonji histone demethylase, epigenetically regulates BCKDHA expression by binding to the BCKDHA gene promoter. BIX exposure also led to a significant decrease in the EGFR level, causing apoptosis in EGFR-TKI (tyrosine kinase inhibitor)-resistant cell lines, which are dependent on EGFR signaling for survival. Taken together, our current data suggest that BIX triggers apoptosis only in EGFR-mutant NSCLC cells via inhibition of BCKDHA-mediated mitochondrial metabolic function.
Abstract
BIX01294 (BIX), an inhibitor of the G9a histone methyltransferase, has been reported to have antitumor activity against a variety of cancers. However, the molecular mechanisms underlying its anticancer effects, particularly those against lung cancer, remain unclear. Here, we report that BIX induces apoptotic cell death in EGFR-mutant non-small cell lung cancer (NSCLC) cells but not in their wild-type counterparts. Treatment with BIX resulted in a significant reduction in the EGFR level and inhibition of EGFR signaling only in EGFR-mutant NSCLC cells, leading to apoptosis. BIX also inhibited mitochondrial metabolic function and decreased the cellular energy levels that are critical for maintaining the EGFR level. Furthermore, BIX transcriptionally downregulated the transcription of branched-chain α-keto acid dehydrogenase (BCKDHA), which is essential for fueling the tricarboxylic acid (TCA) cycle. Interestingly, this BCKDHA downregulation was due to inhibition of Jumanji-domain histone demethylases but not the G9a histone methyltransferase. We observed that KDM3A, a Jumonji histone demethylase, epigenetically regulates BCKDHA expression by binding to the BCKDHA gene promoter. BIX exposure also led to a significant decrease in the EGFR level, causing apoptosis in EGFR-TKI (tyrosine kinase inhibitor)-resistant cell lines, which are dependent on EGFR signaling for survival. Taken together, our current data suggest that BIX triggers apoptosis only in EGFR-mutant NSCLC cells via inhibition of BCKDHA-mediated mitochondrial metabolic function.
참고문헌 (39)
- Molina, J. R., "Non-small cell lung cancer : epidemiology, risk factors, treatment, and survivorship", Mayo Clin. Proc, 83, pp.584~594 (2008)
- Erridge, S. C., "International comparisons of survival from lung cancer: pitfalls and warnings", Nat. Clin. Pract. Oncol., 4, pp.570~577 (2007)
- Siddik, Z. H., "Cisplatin : mode of cytotoxic action and molecular basis of resistance", Oncogene, 22, pp.7265~7279 (2003)
- Guo, G., "Ligand-Independent EGFR Signaling", Cancer Res, 75, pp.3436~3441 (2015)
- Ladanyi, M., "Lung adenocarcinoma : guiding EGFR-targeted therapy and beyond", Mod. Pathol, 21, pp.S16~S22 (2008)
- Paez, J. G., "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Lynch, T. J., "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N. Engl. J. Med, 350, pp.2129~2139 (2004)
- Sharma, S. V., "Epidermal growth factor receptor mutations in lung cancer", Nat. Rev. Cancer, 7, pp.169~181 (2007)
- Sordella, R., "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways", Science, 305, pp.1163~1167 (2004)
- Kobayashi, S., "EGFR mutation and resistance of non-small-cell lung cancer to gefitinib", N. Engl. J. Med, 352, pp.786~792 (2005)
- Morita, S., "Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations", Clin. Cancer Res, 15, pp.4493~4498 (2009)
- Riely, G. J., "Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib", Clin. Cancer Res, 12, pp.839~844 (2006)
- Murtuza, A., "Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer", Cancer Res, 79, pp.689~698 (2019)
- Kubicek, S., "Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase", Mol. Cell, 25, pp.473~481 (2007)
- Cui, J., "EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells", Cancer Cell Int, 15, pp.4~ (2015)
- Kim, Y., "BIX-01294 induces autophagy-associated cell death via EHMT2", G9a dysfunction and intracellular reactive oxygen species production, 2013, pp.9, 2126~2139
- Park, S. E., "Inhibition of EHMT2", G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-kappaB, 2016, pp.7, 39796~39808
- Fan, J. D., "The selective activation of p53 target genes regulated by SMYD2in BIX-01294 induced autophagy-related cell death", PLoS ONE, 10, pp.0116782~ (2015)
- Woo, S. M., "BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression", Cell Death Discov, 4, pp.29~ (2018)
- Wan, H. J., "Inhibition of G9a attenuates cell proliferation via the mitochondrial apoptosis pathway in lung adenocarcinoma", Zhonghua Zhong Liu Za Zhi, 39, pp.13~17 (2017)
- Kim, H., "EHMT2 inhibition induces cell death in human non-small cell lung cancer by altering the cholesterol biosynthesis pathway", Int. J. Mol. Sci, 21, pp.1002~ (2020)
- Nomori, H., "Detection of NK activity and antibody-dependent cellular cytotoxicity of lymphocytes by human tumor clonogenic assay–its correlation with the 51Cr-release assay", Int. J. Cancer, 35, pp.449~455 (1985)
- Rho, J. K., "The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors", Mol. Cancer Res, 7, pp.1736~1743 (2009)
- Kim, J. H., "Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation", Cancer Res, 78, pp.4482~4496 (2018)
- Soria, J. C., "EGFR-mutated oncogeneaddicted non-small cell lung cancer : current trends and future prospects", Cancer Treat. Rev, 38, pp.416~430 (2012)
- Sharifnia, T., "Genetic modifiers of EGFR dependence in non-small cell lung cancer", Proc. Natl Acad. Sci. USA, 111, pp.18661~18666 (2014)
- Jiang, T., "Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer", Transl. Lung. Cancer Res, 3, pp.370~372 (2014)
- Zhang, Z. Y., "Branched-chain amino acids as critical switches in health and disease", Hypertension, 72, pp.1012~1022 (2018)
- Upadhyay, A. K., "An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases", J. Mol. Biol, 416, pp.319~327 (2012)
- Pang, A. L., "Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294", Oncol. Lett, 7, pp.1819~1825 (2014)
- Singh, P. K., "Histone methyl transferases : a class of epigenetic opportunities to counter uncontrolled cell proliferation", Eur. J. Med. Chem, 166, pp.351~368 (2019)
- Cao, H., "Recent progress in histone methyltransferase(G9a)inhibitors as anticancer agents", Eur. J. Med. Chem, 179, pp.537~546 (2019)
- Park, S. Y., "Jumonji histone demethylases as emerging therapeutic targets", Pharmacol. Res, 105, pp.146~151 (2016)
- Hoffmann, I., "The role of histone demethylases in cancer therapy", Mol. Oncol, 6, pp.683~703 (2012)
- Cho, H. S., "The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1", S transition in cancer cells via transcriptional regulation of the HOXA1 gene, 2012, pp.131, E179~E189
- Li, J., "Epigenetic and transcriptional control of the epidermal growth factor receptor(EGFR)regulates the tumor immune microenvironment in pancreatic cancer", Cancer Discov, 3, pp.736~753 (2020)
- Corbet, C., "Cancer cell metabolism and mitochondria : Nutrient plasticity for TCA cycle fueling", Biochim. Biophys. Acta Rev. Cancer, 1868, pp.7~15 (2017)
- Mayers, J. R., "Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers", Science, 353, pp.1161~1165 (2016)
- Sequist, L. V., "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci. Transl. Med., 3, pp.75ra26~ (2011)